Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.
Dow Jones rose on Thursday while the S&P 500 and the Nasdaq built more support at the 50-day moving average in the stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback